aTYR PHARMA INC — Director's Dealing 2017

Sep 5, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2017-08-31

Reporting Person: MENDLEIN JOHN (Director, CEO and Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-31	Common Stock	P	37736	$2.65	Acquired	367883	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-08-31	Warrant to Purchase Common Stock	$4.64	P	14151	Acquired	2019-12-31	Common Stock (14151)	Direct

Footnotes

F1: Represents shares acquired in a private placement pursuant to a Securities Purchase Agreement dated August 27, 2017 by and among the Company and a select group of institutional and accredited investors named therein (the "Securities Purchase Agreement"). Pursuant to the terms of the Securities Purchase Agreement, investors purchased common stock units for $2.65 per common stock unit. Each common stock unit consisted of one share of the Company's Common Stock and a warrant to purchase 0.375 shares of the Company's Common Stock.

F2: Includes 2,500 shares acquired under the Company's 2015 Employee Stock Purchase Plan (ESPP) on May 15, 2017.